Module
Journal Options Hepatitis - Volume 3, Issue 1
Source: Journal Options
Journal Options Hepatitis - Volume 3, Issue 1
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
  
- Hari S. Conjeevaram, MD, MSc
- Adrian M. Di Bisceglie, MD, FACP
- Tarek Hassanein, MD, FACP, FACG, AGAF
|
  
- Donald M. Jensen, MD
- Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
- Robert P. Perrillo, MD
|
 
- K. Rajender Reddy, MD
- Mark S. Sulkowski, MD
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall the rate of sustained HBsAg loss following peginterferon alfa-2b with or without lamivudine therapy
- Discuss on-treatment variables that predict sustained virologic response rates in HCV-infected patients
- Describe the mechanism of resistance to the anti-HCV agent, nitazoxanide
- Summarize the efficacy of sorafenib for patients with advanced hepatocellular carcinoma
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|